Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CABA NASDAQ:CNTB NYSE:DNA NASDAQ:PROK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCABACabaletta Bio$3.01$3.37$1.26▼$4.23$490.80M3.213.16 million shs2.91 million shsCNTBConnect Biopharma$2.12+1.0%$2.49$0.85▼$3.82$132.22M-0.22221,690 shs173,605 shsDNAGinkgo Bioworks$7.87-1.6%$8.11$5.37▼$17.58$522.60M1.791.22 million shs696,360 shsPROKProKidney$1.64-1.2%$1.84$0.54▼$7.13$501.42M1.64965,048 shs774,778 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCABACabaletta Bio0.00%-7.38%-16.16%-1.63%+72.00%CNTBConnect Biopharma+0.95%-2.30%-13.47%-21.19%+158.85%DNAGinkgo Bioworks-1.16%-3.58%-8.40%+15.36%-19.37%PROKProKidney-1.20%-8.89%-6.29%-27.11%+75.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCABACabaletta Bio$3.01$3.37$1.26▼$4.23$490.80M3.213.16 million shs2.91 million shsCNTBConnect Biopharma$2.12+1.0%$2.49$0.85▼$3.82$132.22M-0.22221,690 shs173,605 shsDNAGinkgo Bioworks$7.87-1.6%$8.11$5.37▼$17.58$522.60M1.791.22 million shs696,360 shsPROKProKidney$1.64-1.2%$1.84$0.54▼$7.13$501.42M1.64965,048 shs774,778 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCABACabaletta Bio0.00%-7.38%-16.16%-1.63%+72.00%CNTBConnect Biopharma+0.95%-2.30%-13.47%-21.19%+158.85%DNAGinkgo Bioworks-1.16%-3.58%-8.40%+15.36%-19.37%PROKProKidney-1.20%-8.89%-6.29%-27.11%+75.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCABACabaletta Bio 2.57Moderate Buy$15.50414.95% UpsideCNTBConnect Biopharma 2.86Moderate Buy$7.20239.62% UpsideDNAGinkgo Bioworks 1.67Reduce$8.507.96% UpsidePROKProKidney 2.50Moderate Buy$7.40351.22% UpsideCurrent Analyst Ratings BreakdownLatest CNTB, PROK, DNA, and CABA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026CABACabaletta Bio Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/26/2026CNTBConnect Biopharma Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.005/26/2026CNTBConnect Biopharma Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.005/21/2026CNTBConnect Biopharma Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$4.005/21/2026CNTBConnect Biopharma Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$4.005/18/2026PROKProKidney HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.005/15/2026CABACabaletta Bio Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$2.00 ➝ $4.005/4/2026CNTBConnect Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)5/4/2026CABACabaletta Bio Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$30.004/21/2026PROKProKidney Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CABACabaletta Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCABACabaletta BioN/AN/AN/AN/A$1.16 per shareN/ACNTBConnect Biopharma$60K2,224.59N/AN/A$0.75 per share2.83DNAGinkgo Bioworks$170.15M3.02N/AN/A$8.74 per share0.90PROKProKidney$890K556.60N/AN/A($3.36) per share-0.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCABACabaletta Bio-$167.86M-$1.96N/AN/AN/AN/A-131.58%-96.46%8/6/2026 (Estimated)CNTBConnect Biopharma-$55.48M-$1.15N/AN/AN/AN/A-122.29%-97.07%8/12/2026 (Estimated)DNAGinkgo Bioworks-$312.76M-$5.36N/AN/AN/A-215.41%-56.08%-26.06%8/6/2026 (Estimated)PROKProKidney-$68.99M-$0.53N/AN/AN/A-8,131.50%N/A-21.39%8/11/2026 (Estimated)Latest CNTB, PROK, DNA, and CABA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026PROKProKidney-$0.13-$0.14-$0.01-$0.14$0.10 million$0.23 million5/14/2026Q1 2026CABACabaletta Bio-$0.41-$0.39+$0.02-$0.39$1.67 millionN/A5/12/2026Q1 2026CNTBConnect Biopharma-$0.29-$0.34-$0.05-$0.34N/A$0.02 million5/7/2026Q1 2026DNAGinkgo Bioworks-$1.2112-$1.39-$0.1789-$1.39$42.93 million$19.00 million3/31/2026Q4 2025CNTBConnect Biopharma-$0.30-$0.27+$0.03-$0.27$0.00 million($0.05) million3/23/2026Q4 2025CABACabaletta Bio-$0.45-$0.40+$0.05-$0.40N/AN/A3/18/2026Q4 2025PROKProKidney-$0.16-$0.14+$0.02-$0.13$0.00 million$0.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCABACabaletta BioN/AN/AN/AN/AN/ACNTBConnect BiopharmaN/AN/AN/AN/AN/ADNAGinkgo BioworksN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCABACabaletta BioN/A2.952.95CNTBConnect Biopharma0.013.233.23DNAGinkgo BioworksN/A5.155.15PROKProKidneyN/A9.069.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCABACabaletta BioN/ACNTBConnect Biopharma58.72%DNAGinkgo Bioworks78.63%PROKProKidney51.59%Insider OwnershipCompanyInsider OwnershipCABACabaletta Bio6.44%CNTBConnect Biopharma22.60%DNAGinkgo Bioworks12.69%PROKProKidney39.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCABACabaletta Bio50163.05 million152.55 millionOptionableCNTBConnect Biopharma11062.96 million48.73 millionOptionableDNAGinkgo Bioworks64065.32 million57.03 millionOptionablePROKProKidney3302.06 million181.75 millionOptionableCNTB, PROK, DNA, and CABA HeadlinesRecent News About These CompaniesProKidney Corp. (NASDAQ:PROK) Given Average Rating of "Moderate Buy" by AnalystsJune 5, 2026 | americanbankingnews.comProKidney names first chief technology officer as kidney therapy nears pivotal trial readoutJune 2, 2026 | bizjournals.comProKidney Appoints Kenneth Locke as Chief Technical OfficerJune 2, 2026 | globenewswire.comProKidney shareholders reaffirm board and auditor at 2026 meetingMay 29, 2026 | tipranks.comProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue EstimatesMay 15, 2026 | zacks.comProKidney Corp. Reports Phase 3 PROACT 1 Study Enrollment Progress and Q1 2026 Financial ResultsMay 15, 2026 | quiverquant.comQProKidney Reports First Quarter 2026 Financial Results and Business HighlightsMay 15, 2026 | globenewswire.comProKidney (PROK) Appoints Greg Madison as CCO to Lead Commercial Strategy for RilparencelMay 2, 2026 | finance.yahoo.comProKidney Corp. Class AApril 14, 2026 | edition.cnn.comApril 2026 Penny Stock HighlightsApril 3, 2026 | finance.yahoo.comWhat Makes ProKidney Corp. (PROK) So AttractiveMarch 31, 2026 | insidermonkey.comWhat makes ProKidney Corp. (PROK) so attractiveMarch 31, 2026 | msn.com5 Best Penny Stocks That Could Triple Your MoneyMarch 30, 2026 | insidermonkey.comProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial OfficerMarch 25, 2026 | globenewswire.comProKidney Corp. (NASDAQ:PROK) Given Consensus Recommendation of “Moderate Buy†by BrokeragesMarch 22, 2026 | defenseworld.netDProKidney narrows loss to $150M as it eyes crucial kidney treatment trial resultsMarch 20, 2026 | bizjournals.comTrade Policy Risks: How Evolving U.S. Tariffs and Export Rules Threaten ProKidney Corp.’s Supply Chain and Financial StabilityMarch 20, 2026 | tipranks.comProKidney Reports Full Year 2025 Financial Results and Business HighlightsMarch 19, 2026 | finance.yahoo.com3 Promising Penny Stocks With At Least $600M Market CapFebruary 12, 2026 | finance.yahoo.comProKidney Stock: Differentiated CKD Approach Positions Rilparencel FavorablyJanuary 31, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 20263 ETFs For the Coming Genomics RevolutionBy Nathan Reiff | June 7, 2026CNTB, PROK, DNA, and CABA Company DescriptionsCabaletta Bio NASDAQ:CABA$3.01 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$3.02 +0.02 (+0.50%) As of 06/12/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Connect Biopharma NASDAQ:CNTB$2.12 +0.02 (+0.95%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$2.12 0.00 (-0.24%) As of 06/12/2026 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.Ginkgo Bioworks NYSE:DNA$7.87 -0.13 (-1.59%) Closing price 06/12/2026 03:59 PM EasternExtended Trading$7.87 0.00 (-0.01%) As of 06/12/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.ProKidney NASDAQ:PROK$1.64 -0.02 (-1.20%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$1.67 +0.03 (+1.95%) As of 06/12/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears This Energy Stock Has Quietly Soared 130% in a Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
